Aldose reductase in diabetic complications of the eye
- PMID: 45423
- DOI: 10.1016/0026-0495(79)90057-x
Aldose reductase in diabetic complications of the eye
Abstract
Aldose reductase (AR) appears to initiate the cataractous process in galactosemic and diabetic animals. Sugars in excess are converted to polyols by lens AR. In sugar cataracts, polyols accumulate to levels substantial enough to cause a hypertonicity leading to lens fiber swelling. All other changes appear secondary to polyol accumulation and lens swelling. The development of sugar cataracts can be duplicated in organ culture. In culture, the various changes that occur were minimized or did not occur when inhibitors of AR were included in the medium. Moreover, AR inhibitors were shown to effectively delay the onset of sugar cataract development in animals. A defect in the corneal epithelium of diabetics became apparent in vitrectomy. One manifestation of this problem was the delay in the reepithelialization of denuded corneas. In examining this problem experimentally, the epithelium was removed from the corneas of diabetic and normal rats. The regeneration of epithelium in corneas of diabetic rats required a longer period than in the normal. The possibility that AR, active in the epithelium, was involved in this phenomenon was investigated. The corneal epithelium was removed from both eyes of a diabetic rat. One eye was treated topically with the AR inhibitor CP-45,634 while the other served as control. The eye treated with CP-45,635 regenerated epithelium much more quickly than the untreated eye. Other AR inhibitors had similar beneficial effects.
Similar articles
-
CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.Metabolism. 1979 Apr;28(4 Suppl 1):456-61. doi: 10.1016/0026-0495(79)90056-8. Metabolism. 1979. PMID: 122297
-
The effect of aldose reductase and its inhibition on sugar cataract formation.Metabolism. 1986 Apr;35(4 Suppl 1):15-9. doi: 10.1016/0026-0495(86)90181-2. Metabolism. 1986. PMID: 3083204
-
NIH conference. Aldose reductase and complications of diabetes.Ann Intern Med. 1984 Jul;101(1):82-91. doi: 10.7326/0003-4819-101-1-82. Ann Intern Med. 1984. PMID: 6203454 Review.
-
Aldose reductase in diabetic cataracts.JAMA. 1981 Jul 17;246(3):257-61. JAMA. 1981. PMID: 6787220 No abstract available.
-
[Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors].Rev Med Interne. 1992 Jan-Feb;13(1):69-79. doi: 10.1016/s0248-8663(05)80015-3. Rev Med Interne. 1992. PMID: 1410879 Review. French.
Cited by
-
Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.Diabetologia. 1984 Jun;26(6):445-8. doi: 10.1007/BF00262218. Diabetologia. 1984. PMID: 6432615 Clinical Trial.
-
Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.Curr Diabetes Rev. 2025;21(6):12-31. doi: 10.2174/0115733998290606240521113832. Curr Diabetes Rev. 2025. PMID: 38798207 Review.
-
Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.Pharm Res. 1991 Jan;8(1):112-8. doi: 10.1023/a:1015850911382. Pharm Res. 1991. PMID: 1901647
-
Diabetic cataract-pathogenesis, epidemiology and treatment.J Ophthalmol. 2010;2010:608751. doi: 10.1155/2010/608751. Epub 2010 Jun 17. J Ophthalmol. 2010. PMID: 20634936 Free PMC article.
-
Antioxidative and chemopreventive properties of Vernonia amygdalina and Garcinia biflavonoid.Int J Environ Res Public Health. 2011 Jun;8(6):2533-55. doi: 10.3390/ijerph8062533. Epub 2011 Jun 23. Int J Environ Res Public Health. 2011. PMID: 21776245 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous